Alcohol Accelerates Liver Damage in People Living with Hepatitis C

More comprehensive approaches to care needed, according to a new study in the American Journal of Preventive Medicine

Ann Arbor, MI, May 10, 2016

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use. In addition, hepatitis C-infected adults were three times more likely to drink five or more drinks per day every day at some point in their lives than those without hepatitis C.

Across the United States, alcohol abuse causes almost 88,000 deaths per year, and among those who die, drinking shortens their lives by an average of almost 30 years. Alcohol misuse also places an enormous burden on the economy, costing $223.5 billion per year in the U.S. alone. Alcohol use is especially detrimental to patients with hepatitis C.

“Alcohol promotes faster development of fibrosis and progression to cirrhosis in people living with hepatitis C, making drinking a dangerous and often deadly activity,” said lead investigator Amber L. Taylor, MPH, from the Centers for Disease Control and Prevention’s Division of Viral Hepatitis. “In 2010, alcohol-related liver disease ranked third as a cause of death among people with hepatitis C.”

In order to better understand the link between alcohol use and hepatitis C, investigators examined self-reported alcohol use in relation to hepatitis C status. Using information from the National Health and Nutrition Examination Survey (NHANES), researchers looked at hepatitis C infection rates for four groups: lifetime abstainers, former drinkers, non-excessive current drinkers, and excessive current drinkers. They found that two groups – former drinkers and excessive current drinkers – had a higher prevalence of hepatitis C (2.2 percent and 1.5 percent, respectively) than lifetime abstainers or current non-excessive drinkers (0.4 percent and 0.9 percent, respectively).

A follow-up survey of people who participated in NHANES 2001-2008 and who tested positive for hepatitis C antibodies (indicating they had been infected at some point in their lives) found that 50 percent were unaware of their hepatitis C status before being notified of their positive test by NHANES, mirroring the national trend.

“Half of all people living with hepatitis C are not aware of their infection nor the serious medical risks they face when consuming alcohol,” said Taylor. “This highlights the need for increased diagnosis as well as comprehensive and effective interventions to link hepatitis C-infected individuals to curative treatments now available and provide education and support needed to reduce alcohol use.”

CDC recommends a one-time hepatitis C test for everyone born during 1945-1965, and explicitly recommends screening for alcohol use among individuals who test positive.

The new information provided by this study helps shed more light on the level of alcohol consumption among those living with hepatitis C. It can help guide best practices for both treating patients and steering possible interventions. “The implementation of behavioral screenings to identify at-risk drinking among both hepatitis C-infected and uninfected individuals could prevent alcohol abuse and serve as a platform to educate patients on the associated risks,” concluded Taylor. “Targeted strategies should emphasize testing to increase hepatitis C awareness among undiagnosed people, prevent disease progression, and ultimately link those infected to curative lifesaving treatments.”


Notes for editors
“Possible Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults NHANES 2003–2010,” by Amber L. Taylor, MPH, Maxine Denniston, MSPH, R. Monina Klevens, DDS, MPH, Lela R. McKnight-Eily, PhD, Ruth B. Jiles, PhD, MS, MPH, (doi: 10.1016/j.amepre.2016.02.033),published online in the American Journal of Preventive Medicine, ahead of Volume 50, Issue 9 (September 2016),

Full text of this article is available to credentialed journalists upon request; contact Angela J. Beck at +1 734 764 8775 or Journalists wishing to interview the authors should contact the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention News Media Team at +1 404 639 8895 or

About the American Journal of Preventive Medicine
The American Journal of Preventive Medicine is the official journal of The American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.

The American Journal of Preventive Medicine, with an Impact Factor of 4.527, is ranked 12th in Public, Environmental, and Occupational Health titles and 10th in General & Internal Medicine titles for total number of citations according to the 2014 Journal Citation Reports® published by Thomson Reuters, 2015.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Angela J. Beck, PhD, MPH
Managing Editor
+1 734 764 8775